Alisertib displayed potential for treatment of endocrine-resistant, ER+ metastatic breast cancer patients in combination with fulvestrant (phase I clinical trial) [50] and a prolonged median PFS in patients with advanced breast cancer in combination with paclitaxel (phase II) [49]. Here, ESR1 is linked to breast carcinoma.